|
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
BEFREE |
Besides, p16 methylation was not linked to clinical stage, prostate-specific antigen (PSA) level, and Gleason score (GS) of patients with PCa. p14 methylation was not correlated with PCa in tissue and urine samples.
|
29561434 |
2018 |
|
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
BEFREE |
We and others previously reported that p14 alternative reading frame (ARF) expression is positively correlated with the disease progression and severity of PCa.
|
23449888 |
2013 |
|
Malignant neoplasm of prostate
|
0.330 |
PosttranslationalModification
|
disease |
BEFREE |
Inverse association of p16 INK4a and p14 ARF methylation of the CDKN2a locus in different Gleason scores of prostate cancer.
|
21912429 |
2011 |
|
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
CTD_human |
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
|
17013881 |
2007 |
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
|
17013881 |
2007 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results indicate that expression of p14 FAST from an oncolytic HAdV can improve vector efficacy for the treatment of cancer.
|
31193718 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An Oncolytic Adenovirus Vector Expressing p14 FAST Protein Induces Widespread Syncytium Formation and Reduces Tumor Growth Rate <i>In Vivo</i>.
|
31193718 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There was a significant correlation between the presence of MMTV (identified by p14 immunohistochemistry) in human breast cancers and histological characteristics similar to MMTV positive mouse mammary tumors (<i>p</i> = 0.001).
|
29868468 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In ovarian epithelial carcinogenesis, p16 and p53 show higher immunohistochemical staining frequencies in malignant tumors and are associated with poor prognoses. p14 was only analyzed in carcinomas, with conflicting results.
|
27770808 |
2016 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Adenovirus-Mediated Expression of the p14 Fusion-Associated Small Transmembrane Protein Promotes Cancer Cell Fusion and Apoptosis In Vitro but Does Not Provide Therapeutic Efficacy in a Xenograft Mouse Model of Cancer.
|
26986751 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer.
|
27740615 |
2016 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Loss of p14 expression results in increased MDM2-mediated degradation of the tumour suppressor protein p53, and predisposes mutation carriers to multiple benign and malignant neoplasms.
|
26876133 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, the polyadenylated polycistronic transcripts containing full-size E1ORF and produced from the early P14 promoter were detected for the first time in cervical tumors with episomal forms of the HPV16 genome.
|
26655237 |
2016 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
High frequency of p16 and p14 promoter hypermethylation and marked telomere instability in salivary gland tumors.
|
26351750 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our findings indicate p14 (ARF) variants may predict tumor HPV16-positive SCCOP patients and survival.
|
24104554 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Higher p14 mRNA transcript levels were associated with non-cancerous background tissue specimens (median copy numbers: 103 vs. 4, p=0.0095), with better overall and disease-free survival, and in TNM2 stage tumours (TNM2 vs. TNM1, 27.2 vs. 3.5, p=0.049; TNM1/TNM2 vs. TNM3/4, 26 vs. 2, p=0.009).
|
23645774 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This resulted in underexpression of the tumor suppressor p14 alternate reading frame (p14ARF); the reduced DNA repair was corrected by transfection with p14ARF.
|
23661601 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Promoter hypermethylation occurred frequently in both pathologically normal urothelium and tumor samples from bladder cancer patients, and increased with progression from normal to bladder cancer at E-cadherin (P = 0.067), p16 (P < 0.001), p14 (P = 0.01), and RASSF1A (P = 0.01).
|
20800513 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, Tbx3 expression was found to be suppressed by AFLL when the expression of tumor suppressor genes p14 and p53 were activated.
|
20702496 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Methylation was significantly more frequent (P < 0.05) in cancer than control patients for all genes except p14 and p16.
|
17363525 |
2007 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Of the putative tumour suppressor genes in the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway, only DAP kinase is frequently methylated in MM, which is associated with gene silencing and might be of prognostic significance. p14 and Apaf-1 were not methylated in MM.
|
17557868 |
2007 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The microsatellite instability and CpG island hypermethylation of p14 ( ARF ) and p16 ( INK4a ) are related to the pathogenesis of neoplasia in ulcerative colitis.
|
17665255 |
2007 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The frequency of cancer-related gene methylation in SCCs was: CDH1 (95%), p16 (20%), p14 (15%), DAPK1 (15%), MGMT (15%), RB1 (5%), RASSF1 (5%), p15 (0%), PTEN (0%), PRDM2 (0%) and p53 (0%).
|
17034532 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Methylation of the MLH1, P16, TIMP3 and P14 genes was associated with tumour infiltrating lymphocytes (p < 0.05), microsatellite instability (p < 0.001), BRAF mutation (p < 0.0001) and elevated concentrations of the methyl group carriers tetrahydrofolate (THF) and 5,10-methylene THF (p < 0.05).
|
16981189 |
2006 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
EGFR gene amplification was present in 27 of these tumors (40%), and we identified allelic losses at 7p11 approximately p14 in 38 of the 68 cases (56%), including 17 tumors displaying loss for EGFR intragenic markers.
|
16364761 |
2006 |